Intraday Alerts

PRA Health Sciences (PRAH) Has Broken Out To A New High For The Year

By RTTNews Staff Writer ✉ | Published: 12/13/2017 10:18 AM ET |

PRA Health Sciences (PRAH) has been climbing since the open of trade Wednesday and is currently higher by 3.07 at $87.68.

PRA Health Sciences has broken out of a 2-month trading range this morning and has set a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.

Biotech Stocks Facing FDA Decision In April 2024

Biotech Stocks Facing FDA Decision in March 2024

Biotech Stocks Facing FDA Decision In November 2023

Latest News Videos

Biotechnology Weekly Update - April 24, 2024

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos

Latest Updates on COVID-19

WHO Defines Uniform Terminology For Air-transmitted Pathogens

Scientists Develop Universal Vaccine That May Protect Humans Against Any Virus

Specific Human Nasal Epithelial Cells Protect Children Against COVID: Study

CDC Study Finds Cardiac Deaths Among Young People Not Connected With Covid Vaccines

COVID-19 Fraud Enforcement Task Force Releases 2024 Report

COVID-19: Drugs in Development

Follow RTT

Editor's Pick
Most Read
Most Emailed

ConSup North America Recalls RTE Sliced Prosciutto Product

Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up

Boston Scientific Boosts FY24 Outlook - Update

Roche Q1 Sales Down, Confirms FY24 View; Stock Down

Dr. Reddy's Recalls Sapropterin Dihydrochloride Powder For Oral Solution

PRA Health Sciences (PRAH) Has Broken Out To A New High For The Year

ConSup North America Recalls RTE Sliced Prosciutto Product

Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up

Boston Scientific Boosts FY24 Outlook - Update

Roche Q1 Sales Down, Confirms FY24 View; Stock Down

Dr. Reddy's Recalls Sapropterin Dihydrochloride Powder For Oral Solution

Philip Morris Q1 Results Top Estimates, But Trims FY24 Outlook

Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up

Primal Kitchen Avocado Oil Recalled For Packaging Issue

Tesla Slashes Car Prices In China After US Cuts

Infinite Herbs Recalls Select Fresh Organic Basil

FSIS Alerts Against Ground Beef Products For E. Coli Concern

Vertiv Holdings Lifts Annual Outlook - Update

Astellas Pharma Annual Net Plunges, But Revenue Climbs; Expects 2024 Result To Improve

JTC Acquires JPMorgan's First Republic Trust Company Of Delaware For $21 Mln

New Oriental Education & Technology Q3 Net Income Rises

Roche Q1 Sales Down, Confirms FY24 View; Stock Down

Pfizer's Emblaveo Gets EU Marketing Authorization For Serious Infectious Disease

NextEra Energy Reaffirms FY24, FY25, FY26 Adj. EPS Outlook - Update

Texas Instruments Inc. Reveals Decline In Q1 Profit, but beats estimates

Incyte To Buy Privately Held Escient Pharma

Tesla Slashes Car Prices In China After US Cuts

Verizon Maintains FY24 Earnings Outlook - Update

Western Digital Corp Q3 Earnings Summary

Anglo American To Oppose Any Appeal Relating To Kabwe Claim - Quick Facts

LG Electronics Q1 Net Income Rises, Operating Income Down

Telia Q1 Profit Up; Revenue Declines

Terex Corp. Q1 Profit beats estimates

British American Tobacco Backs Annual Expectations

Keurig Dr Pepper Inc. Q1 Profit Beats Estimates

Rheinmetall Gets Up To EUR 400 Mln Worth Framework Contract From German Armed Forces

Boyd Gaming Corp. Q1 Profit Decreases, misses estimates

Coca-Cola Makes $1.1 Bln Commitment To Microsoft Cloud, Generative AI Capabilities

Drager Q1 Net Income Declines; Confirms FY24 Outlook

Sound Energy Slips To Loss In FY23; Concerned About Continuing As Going Concern; Stock Dips

Dover Corp Q1 Profit Increases, beats estimates